

Laboratory Report

Report prepared for:

Daniel Pocci
Elco Corp
1100 State Road
Ashtabula, OH 44004
Phone: 216-767-4001
Email: d.pocci@italmatch.com, d.bias@italmatch.com, n.massaro@italmatch.com

Report prepared by:

Michelle Mccurdy

Purchase Order:

70336766

For further assistance, contact:

Michelle McCurdy
Technical Manager
PO Box 51610
Knoxville, TN 37950 -1610
(865) 546-1335 ext. 1826
michellemccurdy@galbraith.com

Analysis	Method	Result	Basis	Sample Amount Used	Date (Time)
Sample: Batch: HOKX1329040924 Lot: 093024117					
Lab ID: 2024-U-9095		Received: 2024-10-02			
<i>118: Residue on Ignition (ROI)</i>					
	Reagent Chemicals	NMT 5 ppm	As Received	200.289 g	2024-10-23
<i>408: Color</i>					
	Reagent Chemicals	0 APHA	As Received	100 mL	2024-10-10
<i>680: Ammonium</i>					
	Reagent Chemicals	< 3 ppm	As Received	2.8 mL	2024-10-22
	Reagent Chemicals (matrix spike)	≥ 3 ppm	As Received	2.8 mL	2024-10-22
<i>774: Br/I, Free Br/Cl, SO4/SO3</i>					
	Reagent Chemicals	< 1 ppm	As Received	Direct	2024-10-28
<i>778: Bromide</i>					
	Reagent Chemicals	< 0.005 %	As Received	1.0 mL	2024-10-23
	Reagent Chemicals (matrix spike)	≥ 0.005 %	As Received	1.0 mL	2024-10-23
<i>782: Iron</i>					
	Reagent Chemicals	< 0.2 ppm	As Received	42 mL	2024-10-22
	Reagent Chemicals (matrix spike)	≥ 0.2 ppm	As Received	42 mL	2024-10-22
<i>785: Sulfate</i>					
	Reagent Chemicals	< 1 ppm	As Received	42 mL	2024-10-24
	Reagent Chemicals (matrix spike)	≥ 1 ppm	As Received	42 mL	2024-10-24
<i>cAs: Arsenic Color Method II</i>					
	Reagent Chemicals	< 0.01 ppm	As Received	255 mL	2024-10-29
	Reagent Chemicals (matrix spike)	≥ 0.01 ppm	As Received	255 mL	2024-10-29
<i>f17: Chlorine, Residual Free</i>					
	Reagent Chemicals	< 1 ppm	As Received	50 mL	2024-11-07
	Reagent Chemicals (matrix spike)	≥ 1 ppm	As Received	50 mL	2024-11-07
<i>j35: Hydrochloric Acid</i>					
	Reagent Chemicals	37.3 %	As Received	3.2907 g	2024-10-22

For all samples on this report:

- These analyses were performed in general compliance with the Laboratory sections of Current Good Manufacturing Practices for bulk pharmaceuticals as defined in 21 CFR 210 and 211.

- 2. The matrix spike analysis was performed to satisfy method requirements. There is no additional charge for the matrix spike result.

Signatures:

Published By:	tammy.saylor	2024-11-11T12:23:33.477-05:00
Inspected By:	tammy.saylor	2024-11-11T12:23:29.7-05:00
Created By:	michelle.mccurdy	2024-11-07T21:40:05.743-05:00

- n Physical signatures are on file.
- n "Published By" signature indicates authorized release of data.
- n "Inspected By" signature indicates QA review and approval.